Researchers in NYU Langone’s Division of Neurocritical Care conduct clinical trials to advance the understanding and treatment of patients who are critically ill due to conditions that affect the brain, spine, and peripheral nervous system. Clinical trials and their locations are listed below.

AtRial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA)
Principal investigator (Brooklyn): Aaron S. Lord, MD
Principal investigator (Manhattan): Jose L. Torres, MD

ARCADIA-CSI Cognition and Silent Infarcts—Ancillary Study to the ARCADIA Trial
Principal investigator (Brooklyn): Aaron S. Lord, MD
Principal investigator (Manhattan): Jose L. Torres, MD
Principal investigator (Long Island): Shazia A. Alam, MD

Anticoagulation for Stroke Prevention and Recovery After ICH (ASPIRE)
Principal investigator (Brooklyn): Jennifer A. Frontera, MD

CHARM: Glibenclamide for Large Hemispheric Infarction Analyzing mRS and Mortality
Principal investigator (Manhattan): Kara R. Melmed, MD

Neurological Emergencies Outcomes at NYU
Principal investigator (Brooklyn, Manhattan): Aaron S. Lord, MD

Neuro-AFib Study—Retrospective Phase (Phase I)
Principal investigator: Kara R. Melmed, MD

StATins Use in intRacerebral hemorrhage patieNts (SATURN)
Principal investigator (Brooklyn): Jennifer A. Frontera, MD
Principal investigator (Manhattan): Cen Zhang, MD

Sleep for Stroke Management and Recovery Trial—SleepSMART
Principal investigator (Brooklyn): Aaron S. Lord, MD
Principal investigator (Manhattan): Koto Ishida, MD

A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage In Patients Receiving an Oral Factor Xa Inhibitor
Principal investigator: Jennifer A. Frontera, MD

COVID-19 Post-Hospital Thrombosis Prevention: Post-Hospital Thromboprophylaxis (ACTIV4c)
Principal investigator: Aaron S. Lord, MD

Validation of Early Prognositic Data for Recovery Outcome after Stroke for Future, Higher Yield Trials (VERIFY)
Principal investigator: Heidi Schambra, MD